|
Market Closed -
Nasdaq Stockholm
17:00:00 09/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 161.80 SEK | -2.06% |
|
-4.03% | +2.93% |
| 10-09 | Pareto reiterates Hold on Cellavision, growth target will be difficult to reach | FW |
| 10-05 | Case All Star Small Cap fell 3.28 percent in September - challenging month for small caps | FW |
Company Valuation: CellaVision AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,757 | 5,462 | 5,057 | 5,188 | 3,749 | 3,859 | - | - |
| Change | - | -29.58% | -7.42% | 2.59% | -27.72% | 2.93% | - | - |
| Enterprise Value (EV) 1 | 7,763 | 5,456 | 5,000 | 5,065 | 3,587 | 3,671 | 3,636 | 3,579 |
| Change | - | -29.71% | -8.37% | 1.31% | -29.18% | 2.34% | -0.95% | -1.57% |
| P/E | 61.9x | 46.2x | 38.8x | 36.9x | 24.5x | 27.5x | 21.8x | 19.3x |
| PBR | 14.3x | 8.51x | 7.06x | 6.36x | 4.22x | 3.98x | 3.6x | 3.25x |
| PEG | - | -8.36x | 3.8x | 4.58x | 2.78x | -3.23x | 0.8x | 1.5x |
| Capitalization / Revenue | 13.7x | 8.54x | 7.47x | 7.17x | 4.94x | 4.95x | 4.42x | 4.09x |
| EV / Revenue | 13.7x | 8.53x | 7.38x | 7x | 4.73x | 4.71x | 4.16x | 3.79x |
| EV / EBITDA | 39.6x | 27.5x | 24.2x | 23.2x | 14.9x | 15.9x | 12.8x | 11.4x |
| EV / EBIT | 47.7x | 34.5x | 29.9x | 28.5x | 17.8x | 20.5x | 16.1x | 14x |
| EV / FCF | 68x | 81.1x | 45.1x | 41.4x | 31.4x | 33.7x | 32.2x | 25.5x |
| FCF Yield | 1.47% | 1.23% | 2.22% | 2.42% | 3.19% | 2.96% | 3.11% | 3.92% |
| Dividend per Share 2 | 2 | 2 | 2.25 | 2.5 | 2.75 | 2.75 | 3.133 | 3.4 |
| Rate of return | 0.62% | 0.87% | 1.06% | 1.15% | 1.75% | 1.7% | 1.94% | 2.1% |
| EPS 2 | 5.25 | 4.96 | 5.46 | 5.9 | 6.42 | 5.873 | 7.423 | 8.38 |
| Distribution rate | 38.1% | 40.3% | 41.2% | 42.4% | 42.8% | 46.8% | 42.2% | 40.6% |
| Net sales 1 | 565.6 | 639.3 | 677.3 | 723.2 | 759 | 779.8 | 873.9 | 944 |
| EBITDA 1 | 196.2 | 198.4 | 206.8 | 218.7 | 241.4 | 230.2 | 283.1 | 313.8 |
| EBIT 1 | 162.7 | 158.3 | 167.1 | 177.7 | 202.1 | 178.7 | 226.1 | 255.9 |
| Net income 1 | 125.3 | 118.3 | 130.3 | 140.7 | 153.1 | 140.1 | 179.1 | 202.6 |
| Net Debt 1 | 6.368 | -5.558 | -56.94 | -122.6 | -162.6 | -188.3 | -223.3 | -280.3 |
| Reference price 2 | 325.20 | 229.00 | 212.00 | 217.50 | 157.20 | 161.80 | 161.80 | 161.80 |
| Nbr of stocks (in thousands) | 23,852 | 23,852 | 23,852 | 23,852 | 23,852 | 23,852 | - | - |
| Announcement Date | 04/02/22 | 08/02/23 | 07/02/24 | 06/02/25 | 05/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.55x | 4.71x | 15.95x | 1.7% | 386M | |
| 32.7x | 5.74x | 21.99x | 0.28% | 243B | |
| 37.38x | 6.65x | 21.04x | 0.65% | 155B | |
| 45.29x | 12.18x | 26.88x | -.--% | 150B | |
| 16.16x | 3.23x | 10.53x | -.--% | 61.93B | |
| 34.27x | 6.73x | 21.35x | -.--% | 49.12B | |
| 19.25x | 2.33x | 11.84x | 2.62% | 48.78B | |
| 33.22x | 6.57x | 22.31x | 0.6% | 48.08B | |
| 45.34x | 11.08x | 24.42x | -.--% | 47.95B | |
| 75.94x | 7.19x | 21.91x | -.--% | 42.62B | |
| Average | 36.71x | 6.64x | 19.82x | 0.58% | 84.65B | |
| Weighted average by Cap. | 36.81x | 7.14x | 21.37x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CEVI Stock
- Valuation CellaVision AB
Select your edition
All financial news and data tailored to specific country editions
